News
-
-
PRESS RELEASE
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB -
-
-
-
-
-
-
PRESS RELEASE
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Late-breaking data from NOTUS confirm Dupixent's effectiveness in reducing COPD exacerbations and improving lung function, presented at ATS and published in NEJM -
